866-997-4948(US-Canada Toll Free)

Middle East Respiratory Syndrome (MERS) - Pipeline Review, H1 2017

Published By :

Global Markets Direct

Published Date : Jun 2017

Category :

Pharmaceutical

No. of Pages : 56 Pages

Middle East Respiratory Syndrome (MERS) - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Middle East Respiratory Syndrome (MERS) - Pipeline Review, H1 2017, provides an overview of the Middle East Respiratory Syndrome (MERS) (Infectious Disease) pipeline landscape.

Middle East respiratory syndrome (MERS) is a viral respiratory disease caused by a coronavirus (MERSCoV). Symptoms include fever, cough and shortness of breath. Other symptoms include nausea, vomiting and diarrhea. Pneumonia is common, and sometimes it cause injury to organs, such as the kidneys. Treatment is aimed at relieving symptoms (joint pain and fever) with fluids and medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Middle East Respiratory Syndrome (MERS) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Middle East Respiratory Syndrome (MERS) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Middle East Respiratory Syndrome (MERS) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Middle East Respiratory Syndrome (MERS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical and Discovery stages are 2, 10 and 6 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Middle East Respiratory Syndrome (MERS) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Middle East Respiratory Syndrome (MERS) (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Middle East Respiratory Syndrome (MERS) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Middle East Respiratory Syndrome (MERS) (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Middle East Respiratory Syndrome (MERS) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Middle East Respiratory Syndrome (MERS) (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Middle East Respiratory Syndrome (MERS) (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Middle East Respiratory Syndrome (MERS) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Middle East Respiratory Syndrome (MERS) - Overview
Middle East Respiratory Syndrome (MERS) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Middle East Respiratory Syndrome (MERS) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Middle East Respiratory Syndrome (MERS) - Companies Involved in Therapeutics Development
Atriva Therapeutics GmbH
Autoimmune Technologies LLC
Fab'entech SA
Gilead Sciences Inc
Humabs BioMed SA
Inovio Pharmaceuticals Inc
Nanotherapeutics Inc
NanoViricides Inc
Novavax Inc
Phelix Therapeutics LLC
Planet Biotechnology Inc
Regeneron Pharmaceuticals Inc
Romark Laboratories LC
Middle East Respiratory Syndrome (MERS) - Drug Profiles
3B-11 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ATR-006 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BNSP-333S1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CSW-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Inhibit Cathepsin L for Coronaviridae Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FBR-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FM-2101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GS-5734 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INO-4500 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LCA-60 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Middle East respiratory syndrome coronavirus vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Middle East respiratory syndrome coronavirus vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Middle East respiratory syndrome vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Middle East respiratory syndrome vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Middle East respiratory syndrome vaccine + severe acute respiratory syndrome vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nitazoxanide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
REGN-3048 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
REGN-3051 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SAB-301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Middle East Respiratory Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Middle East Respiratory Syndrome (MERS) - Product Development Milestones
Featured News & Press Releases
Feb 23, 2017: Inovio Reports New Positive Clinical Data on MERS Vaccine GLS-5300
Dec 06, 2016: Inovio MERS Vaccine Development to be Expanded with Funding from International Vaccine Institute
Aug 24, 2016: SAB Biotherapeutics Announces Contract with BARDA to Advance First MERS Treatment
Aug 11, 2016: Phase I Clinical Trials Underway for First MERS Treatment
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Middle East Respiratory Syndrome (MERS), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Middle East Respiratory Syndrome (MERS) - Pipeline by Atriva Therapeutics GmbH, H1 2017
Middle East Respiratory Syndrome (MERS) - Pipeline by Autoimmune Technologies LLC, H1 2017
Middle East Respiratory Syndrome (MERS) - Pipeline by Fab'entech SA, H1 2017
Middle East Respiratory Syndrome (MERS) - Pipeline by Gilead Sciences Inc, H1 2017
Middle East Respiratory Syndrome (MERS) - Pipeline by Humabs BioMed SA, H1 2017
Middle East Respiratory Syndrome (MERS) - Pipeline by Inovio Pharmaceuticals Inc, H1 2017
Middle East Respiratory Syndrome (MERS) - Pipeline by Nanotherapeutics Inc, H1 2017
Middle East Respiratory Syndrome (MERS) - Pipeline by NanoViricides Inc, H1 2017
Middle East Respiratory Syndrome (MERS) - Pipeline by Novavax Inc, H1 2017
Middle East Respiratory Syndrome (MERS) - Pipeline by Phelix Therapeutics LLC, H1 2017
Middle East Respiratory Syndrome (MERS) - Pipeline by Planet Biotechnology Inc, H1 2017
Middle East Respiratory Syndrome (MERS) - Pipeline by Regeneron Pharmaceuticals Inc, H1 2017
Middle East Respiratory Syndrome (MERS) - Pipeline by Romark Laboratories LC, H1 2017

List of Figures
Number of Products under Development for Middle East Respiratory Syndrome (MERS), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Targets, H1 2017
Number of Products by Stage and Targets, H1 2017
Number of Products by Mechanism of Actions, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *